{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T06:06:52Z","timestamp":1767074812020,"version":"3.48.0"},"reference-count":218,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04188-2","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T19:15:38Z","timestamp":1764357338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR\/Cas9, and bacteriotherapy as promising therapeutic strategies"],"prefix":"10.1007","volume":"16","author":[{"given":"Akmal","family":"Zubair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Wdidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"4","key":"4188_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778\u201389.","journal-title":"Int J Cancer"},{"issue":"1","key":"4188_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"Ca Cancer J Clin"},{"issue":"2","key":"4188_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137\u201348.","journal-title":"Immunity"},{"issue":"7","key":"4188_CR4","doi-asserted-by":"publisher","first-page":"17024","DOI":"10.1038\/natrevmats.2017.24","volume":"2","author":"H Chen","year":"2017","unstructured":"Chen H, Zhang W, Zhu G, Xie J, Chen X. Rethinking cancer nanotheranostics. Nat Reviews Mater. 2017;2(7):17024.","journal-title":"Nat Reviews Mater"},{"issue":"12","key":"4188_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/1346-8138.16582","volume":"49","author":"S Feng","year":"2022","unstructured":"Feng S, Song G, Liu L, Liu W, Liang G, Song Z. Allergen-specific immunotherapy induces monocyte\u2010derived dendritic cells but attenuates their maturation and cytokine production in the lesional skin of an atopic dermatitis mouse model. J Dermatol. 2022;49(12):1310\u20139.","journal-title":"J Dermatol"},{"key":"4188_CR6","doi-asserted-by":"publisher","first-page":"106270","DOI":"10.1016\/j.phrs.2022.106270","volume":"181","author":"L Pan","year":"2022","unstructured":"Pan L, Feng F, Wu J, Fan S, Han J, Wang S, et al. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022;181:106270.","journal-title":"Pharmacol Res"},{"issue":"23","key":"4188_CR7","doi-asserted-by":"publisher","first-page":"23998","DOI":"10.1021\/acsnano.3c08875","volume":"17","author":"W Shen","year":"2023","unstructured":"Shen W, Pei P, Zhang C, Li J, Han X, Liu T, et al. A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano. 2023;17(23):23998\u20134011.","journal-title":"ACS Nano"},{"issue":"10","key":"4188_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.chom.2022.09.004","volume":"30","author":"Z Tian","year":"2022","unstructured":"Tian Z, Zhang Y, Zheng Z, Zhang M, Zhang T, Jin J, et al. Gut Microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation. Cell Host Microbe. 2022;30(10):1450\u201363. e8.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"4188_CR9","first-page":"2051","volume":"41","author":"S Chen","year":"2019","unstructured":"Chen S, Zhao Y, Shen F, Long D, Yu T, Lin X. Introduction of exogenous wild\u2013type p53 mediates the regulation of oncoprotein 18\/stathmin signaling via nuclear factor\u2013\u03baB in non\u2013small cell lung cancer NCI\u2013H1299 cells. Oncol Rep. 2019;41(3):2051\u20139.","journal-title":"Oncol Rep"},{"issue":"2","key":"4188_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh CS, Hsu JC, Hosseini I, Shen B-Q, Rotte A, Twomey P, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555\u201370.","journal-title":"Mol Ther"},{"issue":"4","key":"4188_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Reviews Clin Oncol. 2021;18(4):215\u201329.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"6","key":"4188_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2174\/1568009622666220214103533","volume":"22","author":"M Rezaei","year":"2022","unstructured":"Rezaei M, Danilova ND, Soltani M, Savvateeva LV, Tarasov VV, Ganjalikhani-Hakemi M, et al. Cancer vaccine in cold tumors: clinical Landscape, Challenges, and opportunities. Curr Cancer Drug Targets. 2022;22(6):437\u201353.","journal-title":"Curr Cancer Drug Targets"},{"key":"4188_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2022.12.007","volume":"181","author":"G Zhao","year":"2023","unstructured":"Zhao G, Jiang Y, Ma P, Wang S, Nie G, Li N. The clinical landscape of therapeutic cancer vaccines: the next breakthrough in cancer immunotherapy? Eur J Cancer. 2023;181:38\u201341.","journal-title":"Eur J Cancer"},{"issue":"6382","key":"4188_CR14","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, T\u00fcreci \u00d6. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355\u201360.","journal-title":"Science"},{"issue":"1","key":"4188_CR15","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","volume":"12","author":"D Roy","year":"2021","unstructured":"Roy D, Geoffroy K, Marguerie M, Khan S, Martin N, Kmiecik J, et al. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nat Commun. 2021;12(1):2626.","journal-title":"Nat Commun"},{"issue":"17","key":"4188_CR16","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1002\/smll.201600061","volume":"12","author":"AS Cheung","year":"2016","unstructured":"Cheung AS, Koshy ST, Stafford AG, Bastings MM, Mooney DJ. Adjuvant-loaded subcellular vesicles derived from disrupted cancer cells for cancer vaccination. Small. 2016;12(17):2321\u201333.","journal-title":"Small"},{"key":"4188_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s40425-019-0607-z","volume":"7","author":"MO Mohsen","year":"2019","unstructured":"Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, et al. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. J Immunother Cancer. 2019;7:144.","journal-title":"J Immunother Cancer"},{"key":"4188_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jconrel.2018.04.041","volume":"282","author":"R Kuai","year":"2018","unstructured":"Kuai R, Sun X, Yuan W, Ochyl LJ, Xu Y, Najafabadi AH, et al. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. J Controlled Release. 2018;282:131\u20139.","journal-title":"J Controlled Release"},{"issue":"1","key":"4188_CR19","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1038\/s41467-023-40207-y","volume":"14","author":"J Meng","year":"2023","unstructured":"Meng J, Lv Y, Bao W, Meng Z, Wang S, Wu Y, et al. Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. Nat Commun. 2023;14(1):4505.","journal-title":"Nat Commun"},{"key":"4188_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.12.036","volume":"248","author":"KK Ahmed","year":"2017","unstructured":"Ahmed KK, Geary SM, Salem AK. Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines. J Controlled Release. 2017;248:1\u20139.","journal-title":"J Controlled Release"},{"issue":"6","key":"4188_CR21","first-page":"3213","volume":"40","author":"S Wei","year":"2018","unstructured":"Wei S, Sun T, Du J, Zhang B, Xiang D, Li W. Xanthohumol, a prenylated flavonoid from Hops, exerts anticancer effects against gastric cancer in vitro. Oncol Rep. 2018;40(6):3213\u201322.","journal-title":"Oncol Rep"},{"issue":"5","key":"4188_CR22","first-page":"6531","volume":"16","author":"Z Lou","year":"2018","unstructured":"Lou Z, Gong YQ, Zhou X, Hu GH. Low expression of miR\u2013199 in hepatocellular carcinoma contributes to tumor cell hyper\u2013proliferation by negatively suppressing XBP1. Oncol Lett. 2018;16(5):6531\u20139.","journal-title":"Oncol Lett"},{"issue":"41","key":"4188_CR23","doi-asserted-by":"publisher","first-page":"18908","DOI":"10.1021\/jacs.2c06538","volume":"144","author":"K Liu","year":"2022","unstructured":"Liu K, Jiang Z, Lalancette RA, Tang X, J\u00e4kle F. Near-infrared-absorbing B\u2013N Lewis pair-functionalized anthracenes: electronic structure tuning, conformational isomerism, and applications in photothermal cancer therapy. J Am Chem Soc. 2022;144(41):18908\u201317.","journal-title":"J Am Chem Soc"},{"key":"4188_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.copbio.2020.02.009","volume":"65","author":"R Ahmed","year":"2020","unstructured":"Ahmed R, Sayegh N, Graciotti M, Kandalaft LE. Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines. Curr Opin Biotechnol. 2020;65:142\u201355.","journal-title":"Curr Opin Biotechnol"},{"issue":"11","key":"4188_CR25","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.jcyt.2016.09.009","volume":"18","author":"RS Abraham","year":"2016","unstructured":"Abraham RS, Mitchell DA. Gene-modified dendritic cell vaccines for cancer. Cytotherapy. 2016;18(11):1446\u201355.","journal-title":"Cytotherapy"},{"issue":"4","key":"4188_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","volume":"22","author":"NG Kooreman","year":"2018","unstructured":"Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao N-Y, et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell Stem Cell. 2018;22(4):501\u201313. e7.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"4188_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019\u201327.","journal-title":"Clin Cancer Res"},{"key":"4188_CR28","doi-asserted-by":"crossref","unstructured":"Miguel A, Sendra L, No\u00e9 V, Ciudad CJ, Das\u00ed F, Hervas D et al. Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma. OncoTargets Therapy. 2017:503\u201314.","DOI":"10.2147\/OTT.S104393"},{"key":"4188_CR29","doi-asserted-by":"publisher","first-page":"113250","DOI":"10.1016\/j.biopha.2022.113250","volume":"152","author":"J Xia","year":"2022","unstructured":"Xia J, Miao Y, Wang X, Huang X, Dai J. Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine. Biomed Pharmacother. 2022;152:113250.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"4188_CR30","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1172\/JCI81137","volume":"126","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Andr\u00e9 F, Amigorena S, Soria J-C, Eggermont A, Kroemer G, et al. Dendritic cell\u2013derived exosomes for cancer therapy. J Clin Investig. 2016;126(4):1224\u201332.","journal-title":"J Clin Investig"},{"issue":"9","key":"4188_CR31","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1021\/acs.molpharmaceut.2c00407","volume":"19","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Liu T, Zhou M. Immune-cell-derived exosomes for cancer therapy. Mol Pharm. 2022;19(9):3042\u201356.","journal-title":"Mol Pharm"},{"key":"4188_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.actbio.2021.10.041","volume":"138","author":"H Zhu","year":"2022","unstructured":"Zhu H, Wang K, Wang Z, Wang D, Yin X, Liu Y, et al. An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor Inhibition in vivo. Acta Biomater. 2022;138:491\u2013504.","journal-title":"Acta Biomater"},{"issue":"1","key":"4188_CR33","first-page":"221","volume":"3","author":"X Tian","year":"2019","unstructured":"Tian X, Gu T, Patel S, Bode AM, Lee M-H, Dong Z. CRISPR\/Cas9\u2013An evolving biological tool kit for cancer biology and oncology. NPJ Precision Oncol. 2019;3(1):221.","journal-title":"NPJ Precision Oncol"},{"issue":"1","key":"4188_CR34","doi-asserted-by":"publisher","first-page":"1779991","DOI":"10.1080\/2162402X.2020.1779991","volume":"9","author":"M Naseri","year":"2020","unstructured":"Naseri M, Bozorgmehr M, Z\u00f6ller M, Ranaei Pirmardan E, Madjd Z. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Oncoimmunology. 2020;9(1):1779991.","journal-title":"Oncoimmunology"},{"key":"4188_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.actbio.2020.08.008","volume":"115","author":"C Dai Phung","year":"2020","unstructured":"Dai Phung C, Pham TT, Nguyen HT, Nguyen TT, Ou W, Jeong J-H, et al. Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses. Acta Biomater. 2020;115:371\u201382.","journal-title":"Acta Biomater"},{"issue":"4","key":"4188_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jhep.2017.05.019","volume":"67","author":"Z Lu","year":"2017","unstructured":"Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67(4):739\u201348.","journal-title":"J Hepatol"},{"issue":"2","key":"4188_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14712598.2020.1815704","volume":"21","author":"E Faghfuri","year":"2021","unstructured":"Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B. Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin Biol Ther. 2021;21(2):201\u201318.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"4188_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/imt-2022-0036","volume":"14","author":"SA Sadeghi Najafabadi","year":"2022","unstructured":"Sadeghi Najafabadi SA, Bolhassani A, Aghasadeghi MR. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Immunotherapy. 2022;14(8):639\u201354.","journal-title":"Immunotherapy"},{"key":"4188_CR39","doi-asserted-by":"crossref","unstructured":"McNamara MA, Nair SK, Holl EK. RNA-based vaccines in cancer immunotherapy. J Immunol Res. 2015;2015.","DOI":"10.1155\/2015\/794528"},{"issue":"3","key":"4188_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","volume":"25","author":"Z Jahanafrooz","year":"2020","unstructured":"Jahanafrooz Z, Baradaran B, Mosafer J, Hashemzaei M, Rezaei T, Mokhtarzadeh A, et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discovery Today. 2020;25(3):552\u201360.","journal-title":"Drug Discovery Today"},{"issue":"7662","key":"4188_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"key":"4188_CR42","doi-asserted-by":"crossref","unstructured":"Tomb\u00e1cz I, Weissman D, Pardi N. Vaccination with messenger RNA: a promising alternative to DNA vaccination. DNA Vaccines: Methods Protocols. 2021:13\u201331.","DOI":"10.1007\/978-1-0716-0872-2_2"},{"issue":"10","key":"4188_CR43","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/vaccines9101060","volume":"9","author":"M Bidram","year":"2021","unstructured":"Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. mRNA-based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients. Vaccines. 2021;9(10):1060.","journal-title":"Vaccines"},{"issue":"93","key":"4188_CR44","doi-asserted-by":"publisher","first-page":"12417","DOI":"10.1039\/D1CC04846E","volume":"57","author":"X He","year":"2021","unstructured":"He X, Jiang Z, Akakuru OU, Li J, Wu A. Nanoscale covalent organic frameworks: from controlled synthesis to cancer therapy. Chem Commun. 2021;57(93):12417\u201335.","journal-title":"Chem Commun"},{"issue":"7","key":"4188_CR45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/2326-6066.CIR-22-0814","volume":"11","author":"W Liang","year":"2023","unstructured":"Liang W, Liu H, Zeng Z, Liang Z, Xie H, Li W, et al. KRT17 promotes T-lymphocyte infiltration through the YTHDF2\u2013CXCL10 axis in colorectal cancer. Cancer Immunol Res. 2023;11(7):875\u201394.","journal-title":"Cancer Immunol Res"},{"key":"4188_CR46","doi-asserted-by":"crossref","unstructured":"Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA cancer vaccines. Curr Strategies Cancer Gene Therapy. 2016:61\u201385.","DOI":"10.1007\/978-3-319-42934-2_5"},{"issue":"2","key":"4188_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/applmicrobiol2020024","volume":"2","author":"PA Johnson","year":"2022","unstructured":"Johnson PA, Wu A, Johnson JC, Schauer Z, Wu T, Fernandes F, et al. Advances in DNA-and RNA-Based oncolytic viral therapeutics and immunotherapies. Appl Microbiol. 2022;2(2):319\u201329.","journal-title":"Appl Microbiol"},{"issue":"23","key":"4188_CR48","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.3390\/cancers13236041","volume":"13","author":"S Beyaert","year":"2021","unstructured":"Beyaert S, Machiels J-P, Schmitz S. Vaccine-based immunotherapy for head and neck cancers. Cancers. 2021;13(23):6041.","journal-title":"Cancers"},{"key":"4188_CR49","doi-asserted-by":"publisher","first-page":"baaa004","DOI":"10.1093\/database\/baaa004","volume":"2020","author":"X Tan","year":"2020","unstructured":"Tan X, Li D, Huang P, Jian X, Wan H, Wang G, et al. DbPepNeo: a manually curated database for human tumor neoantigen peptides. Database. 2020;2020:baaa004.","journal-title":"Database"},{"issue":"1","key":"4188_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128.","journal-title":"Mol Cancer"},{"issue":"1","key":"4188_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nbt.4313","volume":"37","author":"B Bulik-Sullivan","year":"2019","unstructured":"Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol. 2019;37(1):55\u201363.","journal-title":"Nat Biotechnol"},{"issue":"13","key":"4188_CR52","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.7150\/thno.38742","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Yang J, Wang L, Liu B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics. 2020;10(13):6011\u201323.","journal-title":"Theranostics"},{"issue":"22","key":"4188_CR53","doi-asserted-by":"publisher","first-page":"2105810","DOI":"10.1002\/advs.202105810","volume":"9","author":"W Wang","year":"2022","unstructured":"Wang W, Yuan T, Ma L, Zhu Y, Bao J, Zhao X, et al. Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors. Adv Sci. 2022;9(22):2105810.","journal-title":"Adv Sci"},{"issue":"5","key":"4188_CR54","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1172\/JCI99538","volume":"129","author":"F Chen","year":"2019","unstructured":"Chen F, Zou Z, Du J, Su S, Shao J, Meng F, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Investig. 2019;129(5):2056\u201370.","journal-title":"J Clin Investig"},{"issue":"14","key":"4188_CR55","doi-asserted-by":"publisher","first-page":"266","DOI":"10.21037\/atm.2016.05.15","volume":"4","author":"J Menez-Jamet","year":"2016","unstructured":"Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K. Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Annals Translational Med. 2016;4(14):266.","journal-title":"Annals Translational Med"},{"key":"4188_CR56","doi-asserted-by":"crossref","unstructured":"Abbott M, Ustoyev Y, editors. Cancer and the immune system: the history and background of immunotherapy. Seminars in oncology nursing. Elsevier; 2019.","DOI":"10.1016\/j.soncn.2019.08.002"},{"key":"4188_CR57","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00262-004-0655-0","volume":"54","author":"M Brinkman","year":"2005","unstructured":"Brinkman M, Walter J, Grein S, Thies MJ, Schulz TW, Herrmann M, et al. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol Immunother. 2005;54:611\u201322.","journal-title":"Cancer Immunol Immunother"},{"key":"4188_CR58","doi-asserted-by":"publisher","first-page":"1122110","DOI":"10.3389\/fonc.2023.1122110","volume":"13","author":"M Li","year":"2023","unstructured":"Li M, Wei J, Xue C, Zhou X, Chen S, Zheng L, et al. Dissecting the roles and clinical potential of YY1 in the tumor microenvironment. Front Oncol. 2023;13:1122110.","journal-title":"Front Oncol"},{"issue":"5","key":"4188_CR59","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/v15051109","volume":"15","author":"M Kheirvari","year":"2023","unstructured":"Kheirvari M, Liu H, Tumban E. Virus-like particle vaccines and platforms for vaccine development. Viruses. 2023;15(5):1109.","journal-title":"Viruses"},{"issue":"3","key":"4188_CR60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/vaccines8030481","volume":"8","author":"N Zhang","year":"2020","unstructured":"Zhang N, Li C, Jiang S, Du L. Recent advances in the development of virus-like particle-based flavivirus vaccines. Vaccines. 2020;8(3):481.","journal-title":"Vaccines"},{"issue":"6","key":"4188_CR61","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment. Oncol Rep. 2019;42(6):2183\u201395.","journal-title":"Oncol Rep"},{"key":"4188_CR62","doi-asserted-by":"publisher","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332(22):1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462.","DOI":"10.1001\/jama.2024.19462"},{"issue":"1","key":"4188_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"4188_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","volume":"22","author":"P Braendstrup","year":"2020","unstructured":"Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22(2):57\u201369.","journal-title":"Cytotherapy"},{"issue":"4","key":"4188_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.46989\/001c.124277","volume":"6","author":"ST Bhaskar","year":"2024","unstructured":"Bhaskar ST, Dholaria B, Savani BN, Sengsayadeth S, Oluwole O. Overview of approved CAR-T products and utility in clinical practice. Clin Hematol Int. 2024;6(4):93\u20139.","journal-title":"Clin Hematol Int"},{"key":"4188_CR66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CMAR.S510408","volume":"17","author":"U Goel","year":"2025","unstructured":"Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D. Ciltacabtagene autoleucel for the treatment of Relapsed\/Refractory multiple myeloma: Efficacy, Safety, and place in therapy. Cancer Manag Res. 2025;17:357\u201372.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"4188_CR67","doi-asserted-by":"publisher","first-page":"1924379","DOI":"10.1155\/2020\/1924379","volume":"2020","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, et al. CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res. 2020;2020(1):1924379.","journal-title":"J Immunol Res"},{"issue":"2","key":"4188_CR68","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","volume":"33","author":"EJ Grigor","year":"2019","unstructured":"Grigor EJ, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98\u2013110.","journal-title":"Transfus Med Rev"},{"key":"4188_CR69","doi-asserted-by":"publisher","first-page":"925985","DOI":"10.3389\/fimmu.2022.925985","volume":"13","author":"MP Jogalekar","year":"2022","unstructured":"Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn B-C. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13:925985.","journal-title":"Front Immunol"},{"key":"4188_CR70","doi-asserted-by":"publisher","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","volume":"13","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol. 2022;13:879608.","journal-title":"Front Immunol"},{"key":"4188_CR71","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3389\/fonc.2020.00885","volume":"10","author":"S Sievers","year":"2020","unstructured":"Sievers S, Watson G, Johncy S, Adkins S. Recognizing and grading CAR T-Cell toxicities: an advanced practitioner perspective. Front Oncol. 2020;10:885.","journal-title":"Front Oncol"},{"issue":"4","key":"4188_CR72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/practneurol-2020-002550","volume":"20","author":"L Neill","year":"2020","unstructured":"Neill L, Rees J, Roddie C. Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know. Pract Neurol. 2020;20(4):285\u201393.","journal-title":"Pract Neurol"},{"key":"4188_CR73","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"15","author":"LL Riegler","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323\u201335.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"4188_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/clinpract13010003","volume":"13","author":"AM Basudan","year":"2022","unstructured":"Basudan AM. The role of immune checkpoint inhibitors in cancer therapy. Clin Pract. 2022;13(1):22\u201340.","journal-title":"Clin Pract"},{"key":"4188_CR75","doi-asserted-by":"publisher","first-page":"132315","DOI":"10.1016\/j.snb.2022.132315","volume":"369","author":"L Zhou","year":"2022","unstructured":"Zhou L, Liu Y, Sun H, Li H, Zhang Z, Hao P. Usefulness of enzyme-free and enzyme-resistant detection of complement component 5 to evaluate acute myocardial infarction. Sens Actuators B. 2022;369:132315.","journal-title":"Sens Actuators B"},{"key":"4188_CR76","doi-asserted-by":"publisher","unstructured":"Zhang X, Li H, Wang H, Zhang Q, Deng X, Zhang S, Wang L, Guo C, Zhao F, Yin Y, Zhou T, Zhong J, Feng H, Chen W, Zhang J, Feng H, Hu R. Iron\/ROS\/Itga3 mediated accelerated depletion of hippocampal neural stem cell pool contributes to cognitive impairment after hemorrhagic stroke. Redox Biol. 2024;71:103086. https:\/\/doi.org\/10.1016\/j.redox.2024.103086.","DOI":"10.1016\/j.redox.2024.103086"},{"key":"4188_CR77","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s40265-016-0618-8","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A. Atezolizumab: first global approval. Drugs. 2016;76:1227\u201332.","journal-title":"Drugs"},{"issue":"8","key":"4188_CR78","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"5","key":"4188_CR79","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","volume":"6","author":"NA Rizvi","year":"2020","unstructured":"Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M-J, et al. Durvalumab with or without Tremelimumab vs standard chemotherapy in first-line treatment of metastatic non\u2013small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6(5):661\u201374.","journal-title":"JAMA Oncol"},{"issue":"5","key":"4188_CR80","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/onco.13752","volume":"26","author":"L Mathieu","year":"2021","unstructured":"Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X, et al. FDA approval summary: Atezolizumab and durvalumab in combination with platinum\u2010based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021;26(5):433\u20138.","journal-title":"Oncologist"},{"issue":"5","key":"4188_CR81","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"1","key":"4188_CR82","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.","journal-title":"Nat Commun"},{"key":"4188_CR83","doi-asserted-by":"publisher","first-page":"103596","DOI":"10.1016\/j.critrevonc.2022.103596","volume":"170","author":"M Santoni","year":"2022","unstructured":"Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol\/Hematol. 2022;170:103596.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"Supplement7","key":"4188_CR84","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","volume":"58","author":"SC Weinmann","year":"2019","unstructured":"Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology. 2019;58(Supplement7):vii59\u201367.","journal-title":"Rheumatology"},{"issue":"1","key":"4188_CR85","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87.","journal-title":"BMC Med"},{"issue":"2","key":"4188_CR86","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","volume":"53","author":"S-Q Tang","year":"2021","unstructured":"Tang S-Q, Tang L-L, Mao Y-P, Li W-F, Chen L, Zhang Y, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treatment: Official J Korean Cancer Association. 2021;53(2):339\u201354.","journal-title":"Cancer Res Treatment: Official J Korean Cancer Association"},{"issue":"5","key":"4188_CR87","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/cancers13050989","volume":"13","author":"HJ Albandar","year":"2021","unstructured":"Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to Rechallenge or not? Cancers. 2021;13(5):989.","journal-title":"Cancers"},{"issue":"1","key":"4188_CR88","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","volume":"20","author":"J Choi","year":"2020","unstructured":"Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9.","journal-title":"Immune Netw"},{"issue":"6","key":"4188_CR89","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor Rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):865\u201371.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4188_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","volume":"43","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2020;43(1):1\u20137.","journal-title":"J Immunother"},{"key":"4188_CR91","doi-asserted-by":"crossref","unstructured":"Khan S, Gerber DE, editors. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Seminars in cancer biology. Elsevier; 2020.","DOI":"10.1016\/j.semcancer.2019.06.012"},{"issue":"3","key":"4188_CR92","doi-asserted-by":"publisher","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11(3):e006398.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4188_CR93","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3747\/co.25.4235","volume":"25","author":"G Myers","year":"2018","unstructured":"Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018;25(5):342.","journal-title":"Curr Oncol"},{"issue":"1","key":"4188_CR94","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4188_CR95","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41401-023-01153-z","volume":"45","author":"Q-q Shen","year":"2024","unstructured":"Shen Q-q, Jv X-h, Ma X-z, Li C, Liu L, Jia W-t, et al. Cell senescence induced by toxic interaction between \u03b1-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of parkinson\u2019s disease. Acta Pharmacol Sin. 2024;45(2):268\u201381.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4188_CR96","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/cge.13589","volume":"97","author":"C Jiang","year":"2020","unstructured":"Jiang C, Meng L, Yang B, Luo X. Application of CRISPR\/Cas9 gene editing technique in the study of cancer treatment. Clin Genet. 2020;97(1):73\u201388.","journal-title":"Clin Genet"},{"issue":"5","key":"4188_CR97","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41401-019-0322-9","volume":"41","author":"H Xing","year":"2020","unstructured":"Xing H, Meng L-h. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. Acta Pharmacol Sin. 2020;41(5):583\u20137.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"4188_CR98","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.drudis.2019.02.011","volume":"24","author":"B Liu","year":"2019","unstructured":"Liu B, Saber A, Haisma HJ. CRISPR\/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discovery Today. 2019;24(4):955\u201370.","journal-title":"Drug Discovery Today"},{"issue":"4","key":"4188_CR99","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/biomedicines6040105","volume":"6","author":"M Martinez-Lage","year":"2018","unstructured":"Martinez-Lage M, Puig-Serra P, Menendez P, Torres-Ruiz R, Rodriguez-Perales S. CRISPR\/Cas9 for cancer therapy: hopes and challenges. Biomedicines. 2018;6(4):105.","journal-title":"Biomedicines"},{"key":"4188_CR100","doi-asserted-by":"publisher","first-page":"118525","DOI":"10.1016\/j.lfs.2020.118525","volume":"263","author":"A Hazafa","year":"2020","unstructured":"Hazafa A, Mumtaz M, Farooq MF, Bilal S, Chaudhry SN, Firdous M, et al. CRISPR\/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 2020;263:118525.","journal-title":"Life Sci"},{"issue":"32","key":"4188_CR101","doi-asserted-by":"publisher","first-page":"52541","DOI":"10.18632\/oncotarget.9646","volume":"7","author":"FA Khan","year":"2016","unstructured":"Khan FA, Pandupuspitasari NS, Chun-Jie H, Ao Z, Jamal M, Zohaib A, et al. CRISPR\/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget. 2016;7(32):52541\u201352.","journal-title":"Oncotarget"},{"key":"4188_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01431-6","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, et al. Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021;20:1\u201322.","journal-title":"Mol Cancer"},{"issue":"1","key":"4188_CR103","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13073-015-0178-7","volume":"9","author":"H Mou","year":"2015","unstructured":"Mou H, Kennedy Z, Anderson DG, Yin H, Xue W. Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med. 2015;9(1):53.","journal-title":"Genome Med"},{"key":"4188_CR104","doi-asserted-by":"crossref","unstructured":"Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M, editors. CRISPR\/Cas9 for cancer research and therapy. Seminars in cancer biology. Elsevier; 2019.","DOI":"10.1016\/j.semcancer.2018.04.001"},{"issue":"12","key":"4188_CR105","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","volume":"79","author":"H Mollanoori","year":"2018","unstructured":"Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR\/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018;79(12):876\u201382.","journal-title":"Hum Immunol"},{"issue":"11","key":"4188_CR106","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.molmed.2019.07.007","volume":"25","author":"C Jiang","year":"2019","unstructured":"Jiang C, Lin X, Zhao Z. Applications of CRISPR\/Cas9 technology in the treatment of lung cancer. Trends Mol Med. 2019;25(11):1039\u201349.","journal-title":"Trends Mol Med"},{"issue":"7","key":"4188_CR107","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3950","volume":"15","author":"FJ S\u00e1nchez-Rivera","year":"2015","unstructured":"S\u00e1nchez-Rivera FJ, Jacks T. Applications of the CRISPR\u2013Cas9 system in cancer biology. Nat Rev Cancer. 2015;15(7):387\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4188_CR108","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"29","author":"G Sharma","year":"2021","unstructured":"Sharma G, Sharma AR, Bhattacharya M, Lee S-S, Chakraborty C. CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther. 2021;29(2):571\u201386.","journal-title":"Mol Ther"},{"issue":"1","key":"4188_CR109","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-021-01487-4","volume":"21","author":"MF Rasul","year":"2022","unstructured":"Rasul MF, Hussen BM, Salihi A, Ismael BS, Jalal PJ, Zanichelli A, et al. Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy. Mol Cancer. 2022;21(1):64.","journal-title":"Mol Cancer"},{"key":"4188_CR110","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.3389\/fimmu.2020.02062","volume":"11","author":"M Azangou-Khyavy","year":"2020","unstructured":"Azangou-Khyavy M, Ghasemi M, Khanali J, Boroomand-Saboor M, Jamalkhah M, Soleimani M, et al. CRISPR\/Cas: from tumor gene editing to T cell-based immunotherapy of cancer. Front Immunol. 2020;11:2062.","journal-title":"Front Immunol"},{"key":"4188_CR111","doi-asserted-by":"crossref","unstructured":"Takeda H, Kataoka S, Nakayama M, Ali MA, Oshima H, Yamamoto D et al. CRISPR-Cas9\u2013mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proceedings of the National Academy of Sciences. 2019;116(31):15635-44.","DOI":"10.1073\/pnas.1904714116"},{"key":"4188_CR112","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00280-019-03800-x","volume":"83","author":"W Zhang","year":"2019","unstructured":"Zhang W, Shi L, Zhao Z, Du P, Ye X, Li D, et al. Disruption of CTLA-4 expression on peripheral blood CD8\u2009+\u2009T cell enhances anti-tumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019;83:911\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4188_CR113","doi-asserted-by":"crossref","unstructured":"Zhang X, Cheng C, Sun W, Wang H. Engineering T cells using CRISPR\/Cas9 for cancer therapy. RNA Interference and CRISPR Technologies: Technical Advances and New Therapeutic Opportunities. 2020:419\u2009\u2013\u200933.","DOI":"10.1007\/978-1-0716-0290-4_23"},{"issue":"15","key":"4188_CR114","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.21037\/atm-20-4726","volume":"9","author":"Y Nuzbrokh","year":"2021","unstructured":"Nuzbrokh Y, Ragi SD, Tsang SH. Gene therapy for inherited retinal diseases. Annals Translational Med. 2021;9(15):1278.","journal-title":"Annals Translational Med"},{"issue":"6","key":"4188_CR115","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/cancers15061813","volume":"15","author":"D Stefanoudakis","year":"2023","unstructured":"Stefanoudakis D, Kathuria-Prakash N, Sun AW, Abel M, Drolen CE, Ashbaugh C, et al. The potential revolution of cancer treatment with CRISPR technology. Cancers. 2023;15(6):1813.","journal-title":"Cancers"},{"issue":"2","key":"4188_CR116","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.bbrc.2020.05.172","volume":"529","author":"F Gonzalez-Salinas","year":"2020","unstructured":"Gonzalez-Salinas F, Rojo R, Martinez-Amador C, Herrera-Gamboa J, Trevino V. Transcriptomic and cellular analyses of CRISPR\/Cas9-mediated edition of FASN show Inhibition of aggressive characteristics in breast cancer cells. Biochem Biophys Res Commun. 2020;529(2):321\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"4188_CR117","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","volume":"447","author":"M Chen","year":"2019","unstructured":"Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J. CRISPR-Cas9 for cancer therapy: opportunities and challenges. Cancer Lett. 2019;447:48\u201355.","journal-title":"Cancer Lett"},{"issue":"1","key":"4188_CR118","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"S-W Wang","year":"2022","unstructured":"Wang S-W, Gao C, Zheng Y-M, Yi L, Lu J-C, Huang X-Y, et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57.","journal-title":"Mol Cancer"},{"issue":"1","key":"4188_CR119","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41467-018-03731-w","volume":"9","author":"B Oldrini","year":"2018","unstructured":"Oldrini B, Curiel-Garc\u00eda \u00c1, Marques C, Matia V, Ulu\u00e7kan \u00d6, Gra\u00f1a-Castro O, et al. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nat Commun. 2018;9(1):1466.","journal-title":"Nat Commun"},{"key":"4188_CR120","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.omtm.2019.02.008","volume":"13","author":"L You","year":"2019","unstructured":"You L, Tong R, Li M, Liu Y, Xue J, Lu Y. Advancements and Obstacles of CRISPR-Cas9 technology in translational research. Mol Therapy-Methods Clin Dev. 2019;13:359\u201370.","journal-title":"Mol Therapy-Methods Clin Dev"},{"issue":"11","key":"4188_CR121","doi-asserted-by":"publisher","first-page":"12305","DOI":"10.18632\/oncotarget.7104","volume":"7","author":"MK White","year":"2016","unstructured":"White MK, Khalili K. CRISPR\/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget. 2016;7(11):12305.","journal-title":"Oncotarget"},{"issue":"7","key":"4188_CR122","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/jcmm.14916","volume":"24","author":"FV Jacinto","year":"2020","unstructured":"Jacinto FV, Link W, Ferreira BI. CRISPR\/Cas9-mediated genome editing: from basic research to translational medicine. J Cell Mol Med. 2020;24(7):3766\u201378.","journal-title":"J Cell Mol Med"},{"issue":"13","key":"4188_CR123","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1093\/nar\/gkx490","volume":"45","author":"T Koo","year":"2017","unstructured":"Koo T, Yoon A-R, Cho H-Y, Bae S, Yun C-O, Kim J-S. Selective disruption of an oncogenic mutant allele by CRISPR\/Cas9 induces efficient tumor regression. Nucleic Acids Res. 2017;45(13):7897\u2013908.","journal-title":"Nucleic Acids Res"},{"key":"4188_CR124","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ymeth.2017.03.007","volume":"121","author":"A Guernet","year":"2017","unstructured":"Guernet A, Grumolato L. CRISPR\/Cas9 editing of the genome for cancer modeling. Methods. 2017;121:130\u20137.","journal-title":"Methods"},{"issue":"5","key":"4188_CR125","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jmedgenet-2014-102968","volume":"52","author":"L Xiao-Jie","year":"2015","unstructured":"Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet. 2015;52(5):289\u201396.","journal-title":"J Med Genet"},{"key":"4188_CR126","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00204-015-1504-y","volume":"89","author":"A Pellagatti","year":"2015","unstructured":"Pellagatti A, Dolatshad H, Valletta S, Boultwood J. Application of CRISPR\/Cas9 genome editing to the study and treatment of disease. Arch Toxicol. 2015;89:1023\u201334.","journal-title":"Arch Toxicol"},{"issue":"9","key":"4188_CR127","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1002\/cam4.2257","volume":"8","author":"Q Gao","year":"2019","unstructured":"Gao Q, Dong X, Xu Q, Zhu L, Wang F, Hou Y, et al. Therapeutic potential of CRISPR\/Cas9 gene editing in engineered T-cell therapy. Cancer Med. 2019;8(9):4254\u201364.","journal-title":"Cancer Med"},{"issue":"11","key":"4188_CR128","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/cgt.2015.54","volume":"22","author":"M Sachdeva","year":"2015","unstructured":"Sachdeva M, Sachdeva N, Pal M, Gupta N, Khan I, Majumdar M, et al. CRISPR\/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther. 2015;22(11):509\u201317.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"4188_CR129","doi-asserted-by":"publisher","first-page":"34531","DOI":"10.1038\/srep34531","volume":"6","author":"C Lin","year":"2016","unstructured":"Lin C, Li H, Hao M, Xiong D, Luo Y, Huang C, et al. Increasing the efficiency of CRISPR\/Cas9-mediated precise genome editing of HSV-1 virus in human cells. Sci Rep. 2016;6(1):34531.","journal-title":"Sci Rep"},{"issue":"6481","key":"4188_CR130","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365.","journal-title":"Science"},{"issue":"9","key":"4188_CR131","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398.","journal-title":"Cell Mol Immunol"},{"issue":"6166","key":"4188_CR132","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343(6166):80\u20134.","journal-title":"Science"},{"issue":"1","key":"4188_CR133","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","volume":"23","author":"M Chehelgerdi","year":"2024","unstructured":"Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23(1):9.","journal-title":"Mol Cancer"},{"issue":"8","key":"4188_CR134","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/cells12081103","volume":"12","author":"N Bhokisham","year":"2023","unstructured":"Bhokisham N, Laudermilch E, Traeger LL, Bonilla TD, Ruiz-Estevez M, Becker JR. CRISPR-Cas system: the current and emerging translational landscape. Cells. 2023;12(8):1103.","journal-title":"Cells"},{"issue":"14","key":"4188_CR135","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.7150\/ijms.112724","volume":"22","author":"S Tang","year":"2025","unstructured":"Tang S, Chen X, Tong X, Zhu L. Overcoming the delivery challenges in CRISPR\/Cas9 gene editing for effective cancer treatment: A review of delivery systems. Int J Med Sci. 2025;22(14):3625\u201349.","journal-title":"Int J Med Sci"},{"key":"4188_CR136","first-page":"100097","volume":"7","author":"C Liao","year":"2023","unstructured":"Liao C, Xiao S, Wang X. Bench-to-bedside: translational development landscape of biotechnology in healthcare. Health Sci Rev. 2023;7:100097.","journal-title":"Health Sci Rev"},{"key":"4188_CR137","doi-asserted-by":"publisher","first-page":"1383062","DOI":"10.3389\/fonc.2024.1383062","volume":"14","author":"S Sowmya","year":"2024","unstructured":"Sowmya S, Augustine D, Mushtaq S, Baeshen HA, Ashi H, Hassan RN, et al. Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing. Front Oncol. 2024;14:1383062.","journal-title":"Front Oncol"},{"issue":"6","key":"4188_CR138","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/cancers17060940","volume":"17","author":"E Youssef","year":"2025","unstructured":"Youssef E, Palmer D, Fletcher B, Vaughn R. Exosomes in precision oncology and beyond: from bench to bedside in diagnostics and therapeutics. Cancers. 2025;17(6):940.","journal-title":"Cancers"},{"issue":"2","key":"4188_CR139","doi-asserted-by":"publisher","first-page":"162","DOI":"10.14499\/indonesianjcanchemoprev15iss2pp162-174","volume":"15","author":"K Eskandar","year":"2024","unstructured":"Eskandar K. Nanotechnology in cancer treatment: innovative approaches to overcoming drug resistance in tumors. Indonesian J Cancer Chemoprevention. 2024;15(2):162\u201374.","journal-title":"Indonesian J Cancer Chemoprevention"},{"key":"4188_CR140","doi-asserted-by":"publisher","first-page":"1527600","DOI":"10.3389\/fmed.2024.1527600","volume":"11","author":"E Youssef","year":"2025","unstructured":"Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. 2025;11:1527600.","journal-title":"Front Med"},{"key":"4188_CR141","doi-asserted-by":"publisher","unstructured":"Amen RA, Hassan YM, Essmat RA, Ahmed RH, Azab MM, Shehata NR, Elgazzar MM, El-Sayed WM. Harnessing the microbiome: CRISPR-based gene editing and antimicrobial peptides in combating antibiotic resistance and cancer. Probiotics Antimicrob Proteins. 2025;17(4):1938\u201368. https:\/\/doi.org\/10.1007\/s12602-025-10573-8.","DOI":"10.1007\/s12602-025-10573-8"},{"issue":"4","key":"4188_CR142","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/stcltm\/szac007","volume":"11","author":"I Thuret","year":"2022","unstructured":"Thuret I, Ruggeri A, Angelucci E, Chabannon C. Hurdles to the adoption of gene therapy as a curative option for transfusion-dependent thalassemia. Stem Cells Translational Med. 2022;11(4):407\u201314.","journal-title":"Stem Cells Translational Med"},{"key":"4188_CR143","doi-asserted-by":"publisher","unstructured":"Khan G, Hussain MS. Expanding the potential of gene therapy for duchenne muscular dystrophy. Curr Pharm Des. 2025. https:\/\/doi.org\/10.2174\/0113816128386290250507101412.","DOI":"10.2174\/0113816128386290250507101412"},{"key":"4188_CR144","unstructured":"Kumar DN, Chowdhary DL, Pathuri T, Katta P, Arya L, editors. AI Enhanced-Smart Genome Editing: Integration of CRISPR-Cas9 with Artificial Intelligence for Cancer Treatment. 2024 5th International Conference for Emerging Technology (INCET); 2024: IEEE."},{"issue":"12","key":"4188_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0297-0","volume":"51","author":"MT-Q Duong","year":"2019","unstructured":"Duong MT-Q, Qin Y, You S-H, Min J-J. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019;51(12):1\u201315.","journal-title":"Exp Mol Med"},{"issue":"6564","key":"4188_CR146","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.abf8403","volume":"374","author":"N Pernigoni","year":"2021","unstructured":"Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Cal\u00ec B, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021;374(6564):216\u201324.","journal-title":"Science"},{"issue":"12","key":"4188_CR147","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/vaccines9121497","volume":"9","author":"KH Gupta","year":"2021","unstructured":"Gupta KH, Nowicki C, Giurini EF, Marzo AL, Zloza A. Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy. Vaccines. 2021;9(12):1497.","journal-title":"Vaccines"},{"issue":"2","key":"4188_CR148","first-page":"147","volume":"19","author":"S Li","year":"2022","unstructured":"Li S, Liu J, Zheng X, Ren L, Yang Y, Li W, et al. Tumorigenic bacteria in colorectal cancer: mechanisms and treatments. Cancer Biology Med. 2022;19(2):147.","journal-title":"Cancer Biology Med"},{"issue":"6","key":"4188_CR149","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1002\/cam4.2148","volume":"8","author":"M Sedighi","year":"2019","unstructured":"Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med. 2019;8(6):3167\u201381.","journal-title":"Cancer Med"},{"issue":"1","key":"4188_CR150","doi-asserted-by":"publisher","first-page":"26","DOI":"10.29252\/pbp.2.1.26","volume":"2","author":"E Khadem","year":"2020","unstructured":"Khadem E, Nafari AH, Safarzadeh A, Falavand Jozaei R, Almasian M, Elyasi H. The role of bacteria in the treatment of cancer: A comprehensive review. Plant Biotechnol Persa. 2020;2(1):26\u201334.","journal-title":"Plant Biotechnol Persa"},{"issue":"7","key":"4188_CR151","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.trecan.2021.01.010","volume":"7","author":"C-B Zhou","year":"2021","unstructured":"Zhou C-B, Zhou Y-L, Fang J-Y. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer. 2021;7(7):647\u201360.","journal-title":"Trends Cancer"},{"key":"4188_CR152","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00284-019-01679-8","volume":"76","author":"A G\u00f3rska","year":"2019","unstructured":"G\u00f3rska A, Przystupski D, Niemczura MJ, Kulbacka J. Probiotic bacteria: a promising tool in cancer prevention and therapy. Curr Microbiol. 2019;76:939\u201349.","journal-title":"Curr Microbiol"},{"key":"4188_CR153","doi-asserted-by":"publisher","first-page":"911783","DOI":"10.3389\/fimmu.2022.911783","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Peng X, Xu B, Zhou X, Chen J, Cheng L. Current status and future directions of bacteria-based immunotherapy. Front Immunol. 2022;13:911783.","journal-title":"Front Immunol"},{"issue":"12","key":"4188_CR154","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41565-019-0589-5","volume":"14","author":"W Song","year":"2019","unstructured":"Song W, Anselmo AC, Huang L. Nanotechnology intervention of the Microbiome for cancer therapy. Nat Nanotechnol. 2019;14(12):1093\u2013103.","journal-title":"Nat Nanotechnol"},{"issue":"6","key":"4188_CR155","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.apsb.2020.01.009","volume":"10","author":"Q Guo","year":"2020","unstructured":"Guo Q, Jiang C. Delivery strategies for macromolecular drugs in cancer therapy. Acta Pharm Sinica B. 2020;10(6):979\u201386.","journal-title":"Acta Pharm Sinica B"},{"issue":"11","key":"4188_CR156","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discovery. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"4188_CR157","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","volume":"25","author":"BA Helmink","year":"2019","unstructured":"Helmink BA, Khan MW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377\u201388.","journal-title":"Nat Med"},{"issue":"2","key":"4188_CR158","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","volume":"164","author":"D Chrysostomou","year":"2023","unstructured":"Chrysostomou D, Roberts LA, Marchesi JR, Kinross JM. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology. 2023;164(2):198\u2013213.","journal-title":"Gastroenterology"},{"issue":"10","key":"4188_CR159","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2020-321153","volume":"69","author":"WY Cheng","year":"2020","unstructured":"Cheng WY, Wu C-Y, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69(10):1867\u201376.","journal-title":"Gut"},{"issue":"4","key":"4188_CR160","first-page":"187","volume":"19","author":"M-R Wu","year":"2019","unstructured":"Wu M-R, Jusiak B, Lu TK. Engineering advanced cancer therapies with synthetic biology. Nat Rev Cancer. 2019;19(4):187\u201395.","journal-title":"Nat Rev Cancer"},{"key":"4188_CR161","doi-asserted-by":"publisher","first-page":"119226","DOI":"10.1016\/j.biomaterials.2019.119226","volume":"214","author":"F Chen","year":"2019","unstructured":"Chen F, Zang Z, Chen Z, Cui L, Chang Z, Ma A, et al. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials. 2019;214:119226.","journal-title":"Biomaterials"},{"issue":"1","key":"4188_CR162","first-page":"560","volume":"8","author":"P Sima","year":"2020","unstructured":"Sima P, Vetvicka V, Vannucci L. J Tumor J Tumor. 2020;8(1):560\u20134.","journal-title":"J Tumor J Tumor"},{"issue":"10","key":"4188_CR163","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3390\/cancers14102413","volume":"14","author":"H Ter\u00e1n-Navarro","year":"2022","unstructured":"Ter\u00e1n-Navarro H, Zeoli A, Salines-Cuevas D, Marradi M, Montoya N, Gonzalez-Lopez E, et al. Gold glyconanoparticles combined with 91\u201399 peptide of the bacterial Toxin, Listeriolysin O, are efficient immunotherapies in experimental bladder tumors. Cancers. 2022;14(10):2413.","journal-title":"Cancers"},{"key":"4188_CR164","doi-asserted-by":"publisher","unstructured":"Aguilera-Herce J, Garc\u00eda-Quintanilla M, Romero-Flores R, McConnell MJ, Ramos-Morales F. A live Salmonella vaccine delivering PcrV through the type III secretion system protects against Pseudomonas aeruginosa. Msphere. 2019;4(2). https:\/\/doi.org\/10.1128\/msphere. 00116\u2009\u2013\u200919.","DOI":"10.1128\/msphere"},{"issue":"4","key":"4188_CR165","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/vaccines8040646","volume":"8","author":"B Troxell","year":"2020","unstructured":"Troxell B, Mendoza M, Ali R, Koci M, Hassan H. Attenuated Salmonella enterica serovar typhimurium, strain NC983, is immunogenic, and protective against virulent typhimurium challenges in mice. Vaccines. 2020;8(4):646.","journal-title":"Vaccines"},{"issue":"12","key":"4188_CR166","doi-asserted-by":"publisher","first-page":"2205641","DOI":"10.1002\/advs.202205641","volume":"10","author":"Y Liu","year":"2023","unstructured":"Liu Y, Niu L, Li N, Wang Y, Liu M, Su X, et al. Bacterial-Mediated tumor therapy: old treatment in a new context. Adv Sci. 2023;10(12):2205641.","journal-title":"Adv Sci"},{"key":"4188_CR167","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/B978-0-323-99336-4.00012-4","volume-title":"Microbiome therapeutics for the cancer management","author":"A Punetha","year":"2023","unstructured":"Punetha A, Punetha AK. Microbiome therapeutics for the cancer management. Microbiome Therapeutics: Elsevier; 2023. pp. 197\u2013230."},{"key":"4188_CR168","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jconrel.2020.07.009","volume":"326","author":"Z Cao","year":"2020","unstructured":"Cao Z, Liu J. Bacteria and bacterial derivatives as drug carriers for cancer therapy. J Controlled Release. 2020;326:396\u2013407.","journal-title":"J Controlled Release"},{"key":"4188_CR169","doi-asserted-by":"publisher","first-page":"117398","DOI":"10.1016\/j.lfs.2020.117398","volume":"246","author":"G Laliani","year":"2020","unstructured":"Laliani G, Sorboni SG, Lari R, Yaghoubi A, Soleimanpour S, Khazaei M, et al. Bacteria and cancer: different sides of the same coin. Life Sci. 2020;246:117398.","journal-title":"Life Sci"},{"issue":"12","key":"4188_CR170","doi-asserted-by":"publisher","first-page":"2104643","DOI":"10.1002\/smll.202104643","volume":"18","author":"T Yin","year":"2022","unstructured":"Yin T, Diao Z, Blum NT, Qiu L, Ma A, Huang P. Engineering bacteria and bionic bacterial derivatives with nanoparticles for cancer therapy. Small. 2022;18(12):2104643.","journal-title":"Small"},{"issue":"9","key":"4188_CR171","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1158\/0008-5472.CAN-04-3002","volume":"65","author":"F Avogadri","year":"2005","unstructured":"Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 2005;65(9):3920\u20137.","journal-title":"Cancer Res"},{"key":"4188_CR172","doi-asserted-by":"publisher","first-page":"114085","DOI":"10.1016\/j.addr.2021.114085","volume":"181","author":"S-R Kang","year":"2022","unstructured":"Kang S-R, Nguyen D-H, Yoo SW, Min J-J. Bacteria and bacterial derivatives as delivery carriers for immunotherapy. Adv Drug Deliv Rev. 2022;181:114085.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4188_CR173","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/PPO.0000000000000647","volume":"29","author":"H Attebury","year":"2023","unstructured":"Attebury H, Daley D. The gut Microbiome and pancreatic cancer development and treatment. Cancer J. 2023;29(2):49\u201356.","journal-title":"Cancer J"},{"key":"4188_CR174","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s12275-012-2090-9","volume":"50","author":"M Yun","year":"2012","unstructured":"Yun M, Pan S, Jiang S-N, Nguyen VH, Park S-H, Jung C-H, et al. Effect of Salmonella treatment on an implanted tumor (CT26) in a mouse model. J Microbiol. 2012;50:502\u201310.","journal-title":"J Microbiol"},{"key":"4188_CR175","doi-asserted-by":"publisher","first-page":"914575","DOI":"10.3389\/fmicb.2022.914575","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, Guo Y, Sun Y, Chen Y, Tan W, Min J-J, et al. Comparison of anticancer activities and biosafety between Salmonella enterica serovar typhimurium \u2206ppGpp and VNP20009 in a murine cancer model. Front Microbiol. 2022;13:914575.","journal-title":"Front Microbiol"},{"issue":"1","key":"4188_CR176","doi-asserted-by":"publisher","first-page":"188388","DOI":"10.1016\/j.bbcan.2020.188388","volume":"1874","author":"A Yaghoubi","year":"2020","unstructured":"Yaghoubi A, Khazaei M, Jalili S, Hasanian SM, Avan A, Soleimanpour S, et al. Bacteria as a double-action sword in cancer. Biochim Et Biophys Acta (BBA)-Reviews Cancer. 2020;1874(1):188388.","journal-title":"Biochim Et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"1","key":"4188_CR177","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1196\/annals.1414.036","volume":"1138","author":"BK Al-Ramadi","year":"2008","unstructured":"Al-Ramadi BK, Fernandez\u2010Cabezudo MJ, El\u2010Hasasna H, Al\u2010Salam S, Attoub S, Xu D, et al. Attenuated bacteria as effectors in cancer immunotherapy. Ann N Y Acad Sci. 2008;1138(1):351\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"4188_CR178","doi-asserted-by":"publisher","first-page":"116839","DOI":"10.1016\/j.lfs.2019.116839","volume":"235","author":"LR Weerakkody","year":"2019","unstructured":"Weerakkody LR, Witharana C. The role of bacterial toxins and spores in cancer therapy. Life Sci. 2019;235:116839.","journal-title":"Life Sci"},{"issue":"2","key":"4188_CR179","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1039\/D0CS00152J","volume":"50","author":"G-F Luo","year":"2021","unstructured":"Luo G-F, Chen W-H, Zeng X, Zhang X-Z. Cell primitive-based biomimetic functional materials for enhanced cancer therapy. Chem Soc Rev. 2021;50(2):945\u201385.","journal-title":"Chem Soc Rev"},{"key":"4188_CR180","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","volume":"10","author":"J G\u00fcnther","year":"2019","unstructured":"G\u00fcnther J, D\u00e4britz J, Wirthgen E. Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment. Front Immunol. 2019;10:1801.","journal-title":"Front Immunol"},{"issue":"9","key":"4188_CR181","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Reviews Clin Oncol. 2021;18(9):558\u201376.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"4188_CR182","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","volume":"109","author":"J-S Kim","year":"2020","unstructured":"Kim J-S, Jun S-Y, Kim Y-S. Critical issues in the development of immunotoxins for anticancer therapy. J Pharm Sci. 2020;109(1):104\u201315.","journal-title":"J Pharm Sci"},{"key":"4188_CR183","doi-asserted-by":"publisher","first-page":"111619","DOI":"10.1016\/j.biopha.2021.111619","volume":"139","author":"R Mirzaei","year":"2021","unstructured":"Mirzaei R, Afaghi A, Babakhani S, Sohrabi MR, Hosseini-Fard SR, Babolhavaeji K, et al. Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother. 2021;139:111619.","journal-title":"Biomed Pharmacother"},{"key":"4188_CR184","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3389\/fimmu.2019.02388","volume":"10","author":"Z Urban-Wojciuk","year":"2019","unstructured":"Urban-Wojciuk Z, Khan MM, Oyler BL, F\u00e5hraeus R, Marek-Trzonkowska N, Nita-Lazar A, et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front Immunol. 2019;10:2388.","journal-title":"Front Immunol"},{"issue":"1","key":"4188_CR185","doi-asserted-by":"publisher","first-page":"1800219","DOI":"10.1002\/adbi.201800219","volume":"3","author":"AV Kroll","year":"2019","unstructured":"Kroll AV, Jiang Y, Zhou J, Holay M, Fang RH, Zhang L. Biomimetic nanoparticle vaccines for cancer therapy. Adv Biosystems. 2019;3(1):1800219.","journal-title":"Adv Biosystems"},{"issue":"10","key":"4188_CR186","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1002\/jcp.28436","volume":"234","author":"G Wang","year":"2019","unstructured":"Wang G, Yu Y, Wang YZ, Wang JJ, Guan R, Sun Y, et al. Role of SCFAs in gut Microbiome and Glycolysis for colorectal cancer therapy. J Cell Physiol. 2019;234(10):17023\u201349.","journal-title":"J Cell Physiol"},{"issue":"9","key":"4188_CR187","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.3390\/cancers12092465","volume":"12","author":"A Laborda-Illanes","year":"2020","unstructured":"Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, Jimenez-Rodriguez B, Lavado R, Comino-M\u00e9ndez I, et al. Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers. 2020;12(9):2465.","journal-title":"Cancers"},{"issue":"3","key":"4188_CR188","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2025.01.029","volume":"33","author":"A Senevirathne","year":"2025","unstructured":"Senevirathne A, Lloren KKS, Aganja RP, Kwon J, Lee JH. Transforming bacterial pathogens into Wonder tools in cancer immunotherapy. Mol Ther. 2025;33(3):866\u201382.","journal-title":"Mol Ther"},{"key":"4188_CR189","doi-asserted-by":"publisher","first-page":"104141","DOI":"10.1016\/j.critrevonc.2023.104141","volume":"191","author":"SRU Din","year":"2023","unstructured":"Din SRU, Saeed S, Khan SU, Arbi FM, Xuefang G, Zhong M. Bacteria-driven cancer therapy: exploring advancements and challenges. Crit Rev Oncol\/Hematol. 2023;191:104141.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"4188_CR190","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/MRM.0000000000000120","volume":"29","author":"W Pan","year":"2018","unstructured":"Pan W, Kang Y. Role of the microbiota in cancer growth and necrosis: the challenges and opportunities of bacteriotherapy for cancer and its complications. Reviews Res Med Microbiol. 2018;29(1):20\u20133.","journal-title":"Reviews Res Med Microbiol"},{"key":"4188_CR191","doi-asserted-by":"publisher","first-page":"1217095","DOI":"10.3389\/fonc.2023.1217095","volume":"13","author":"EA Henderson","year":"2023","unstructured":"Henderson EA, Lukomski S, Boone BA. Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer. Front Oncol. 2023;13:1217095.","journal-title":"Front Oncol"},{"key":"4188_CR192","doi-asserted-by":"publisher","unstructured":"Tieu MV, Pham DT, Cho S. Bacteria-based cancer therapy: looking forward. Biochim Biophys Acta Rev Cancer. 2024;1879(4):189112. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189112.","DOI":"10.1016\/j.bbcan.2024.189112"},{"issue":"1","key":"4188_CR193","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12964-024-01622-w","volume":"22","author":"A Yarahmadi","year":"2024","unstructured":"Yarahmadi A, Zare M, Aghayari M, Afkhami H, Jafari GA. Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future. Cell Communication Signal. 2024;22(1):239.","journal-title":"Cell Communication Signal"},{"issue":"23","key":"4188_CR194","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.3390\/ijms20235880","volume":"20","author":"A Yaghoubi","year":"2019","unstructured":"Yaghoubi A, Khazaei M, Hasanian SM, Avan A, Cho C, Soleimanpour W. Bacteriotherapy in breast cancer. Int J Mol Sci. 2019;20(23):5880.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4188_CR195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25163\/microbbioacts.617330","volume":"6","author":"MS Sultan","year":"2023","unstructured":"Sultan MS. Challenges of breast cancer treatment through microbial therapeutic delivery. Microb Bioactives. 2023;6(1):1\u201315.","journal-title":"Microb Bioactives"},{"issue":"8","key":"4188_CR196","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","volume":"21","author":"S-Y Kwon","year":"2024","unstructured":"Kwon S-Y, Thi-Thu Ngo H, Son J, Hong Y, Min J-J. Exploiting bacteria for cancer immunotherapy. Nat Reviews Clin Oncol. 2024;21(8):569\u201389.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"23","key":"4188_CR197","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022.","journal-title":"Oncotarget"},{"issue":"1","key":"4188_CR198","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12916-023-02852-4","volume":"21","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Edil BH, Li M. Combination therapies for cancer: challenges and opportunities. BMC Med. 2023;21(1):171.","journal-title":"BMC Med"},{"issue":"6","key":"4188_CR199","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ijc.28261","volume":"134","author":"F Li","year":"2014","unstructured":"Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer. 2014;134(6):1257\u201369.","journal-title":"Int J Cancer"},{"issue":"1","key":"4188_CR200","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1186\/s12885-018-4792-9","volume":"18","author":"VI Kiselev","year":"2018","unstructured":"Kiselev VI, Ashrafyan LA, Muyzhnek EL, Gerfanova EV, Antonova IB, Aleshikova OI, et al. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. BMC Cancer. 2018;18(1):904.","journal-title":"BMC Cancer"},{"issue":"1","key":"4188_CR201","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Therapy. 2024;9(1):175.","journal-title":"Signal Transduct Target Therapy"},{"issue":"11","key":"4188_CR202","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"4188_CR203","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/biomedicines8030061","volume":"8","author":"V Schirrmacher","year":"2020","unstructured":"Schirrmacher V. Cancer vaccines and oncolytic viruses exert profoundly lower side effects in cancer patients than other systemic therapies: A comparative analysis. Biomedicines. 2020;8(3):61.","journal-title":"Biomedicines"},{"issue":"9","key":"4188_CR204","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2174\/1389201021666201016142408","volume":"22","author":"M Hoda","year":"2021","unstructured":"Hoda M. Potential alternatives to conventional cancer therapeutic approaches: the way forward. Curr Pharm Biotechnol. 2021;22(9):1141\u20138.","journal-title":"Curr Pharm Biotechnol"},{"issue":"8","key":"4188_CR205","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/molecules27082466","volume":"27","author":"D Tsvetkova","year":"2022","unstructured":"Tsvetkova D, Ivanova S. Application of approved cisplatin derivatives in combination therapy against different cancer diseases. Molecules. 2022;27(8):2466.","journal-title":"Molecules"},{"issue":"2","key":"4188_CR206","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","volume":"33","author":"TK Eggersmann","year":"2019","unstructured":"Eggersmann TK, Degenhardt T, Gluz O, Wuerstlein R, Harbeck N. CDK4\/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, ribociclib and abemaciclib. BioDrugs. 2019;33(2):125\u201335.","journal-title":"BioDrugs"},{"issue":"4","key":"4188_CR207","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489\u201398.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4188_CR208","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","volume":"103","author":"GM Videtic","year":"2019","unstructured":"Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiation Oncology* Biology* Phys. 2019;103(5):1077\u201384.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"1","key":"4188_CR209","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo AC, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24\u201338.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"4188_CR210","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"issue":"4","key":"4188_CR211","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3390\/biomedicines10040832","volume":"10","author":"A-L Mueller","year":"2022","unstructured":"Mueller A-L, Brockmueller A, Fahimi N, Ghotbi T, Hashemi S, Sadri S, et al. Bacteria-mediated modulatory strategies for colorectal cancer treatment. Biomedicines. 2022;10(4):832.","journal-title":"Biomedicines"},{"key":"4188_CR212","unstructured":"Saha S, Mollick S, Zaman S. The uses of bacteria in cancer therapy. Brac University; 2021."},{"issue":"7","key":"4188_CR213","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17425247.2023.2241367","volume":"20","author":"T Gong","year":"2023","unstructured":"Gong T, Wu J. Synthetic engineered bacteria for cancer therapy. Expert Opin Drug Deliv. 2023;20(7):993\u20131013.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"4188_CR214","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41232-020-00153-4","volume":"41","author":"Y Yoshimatsu","year":"2021","unstructured":"Yoshimatsu Y, Mikami Y, Kanai T. Bacteriotherapy for inflammatory bowel disease. Inflamm Regeneration. 2021;41(1):3.","journal-title":"Inflamm Regeneration"},{"issue":"3","key":"4188_CR215","first-page":"273","volume":"28","author":"W Wawrety","year":"2025","unstructured":"Wawrety W, Kedziora A. Role of bacteria in cancers and their therapeutic potential: review of current knowledge. Iran J Basic Med Sci. 2025;28(3):273.","journal-title":"Iran J Basic Med Sci"},{"issue":"20","key":"4188_CR216","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.3390\/ijms21207575","volume":"21","author":"SS Sawant","year":"2020","unstructured":"Sawant SS, Patil SM, Gupta V, Kunda NK. Microbes as medicines: Harnessing the power of bacteria in advancing cancer treatment. Int J Mol Sci. 2020;21(20):7575.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4188_CR217","doi-asserted-by":"publisher","first-page":"e02531","DOI":"10.1128\/spectrum.02531-22","volume":"10","author":"SW Ryu","year":"2022","unstructured":"Ryu SW, Kim J-S, Oh BS, Choi WJ, Yu SY, Bak JE, et al. Gut microbiota Eubacterium callanderi exerts anti-colorectal cancer activity. Microbiol Spectr. 2022;10(6):e02531\u201322.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"4188_CR218","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12943-019-1008-0","volume":"18","author":"M-Y Wei","year":"2019","unstructured":"Wei M-Y, Shi S, Liang C, Meng Q-C, Hua J, Zhang Y-Y, et al. The microbiota and Microbiome in pancreatic cancer: more influential than expected. Mol Cancer. 2019;18(1):97.","journal-title":"Mol Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04188-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T06:04:43Z","timestamp":1767074683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04188-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":218,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4188"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04188-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2343"}}